Lilly's experimental diabetes drug shows promise

Eli Lilly and Company revealed positive top-line results from its Phase 3 TRANSCEND-T2D-1 clinical trial for retatrutide, an experimental drug targeting type 2 diabetes. The study demonstrated significant reductions in A1C levels and body weight among participants. This outcome underscores the drug's potential as a novel therapeutic option in the competitive landscape of diabetes and weight management treatments.